Mankind Pharma Q1 Results: PAT soars 66% YoY to Rs 487 crore on strong all-round show

Operating profit, calculated as earnings before interest, taxes, depreciation and amortisation (EBITDA) for the quarter surged 43% YoY to Rs 660 crore, with margins expanding by a staggering 450 basis points to 25.6%.

More To Explore